Sugawara Eri, Kato Masaru, Hisada Ryo, Oku Kenji, Bohgaki Toshiyuki, Horita Tetsuya, Yasuda Shinsuke, Atsumi Tatsuya
Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Japan.
Intern Med. 2017;56(4):445-448. doi: 10.2169/internalmedicine.56.7668. Epub 2017 Feb 15.
Pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE) or mixed connective tissue disease (MTCD), in contrast to other types of PAH, may respond to immunosuppressive therapy. Most PAH cases with an immunosuppressant response were in the early stages of the disease (WHO functional class III or less). The present case was a 34-year-old woman with MCTD-associated PAH (WHO functional class IV) who was resistant to a combination of three vasodilators. Afterwards, she was treated with glucocorticoid and cyclophosphamide. This case suggested the potential benefit of immunosuppressants in patients with severe MCTD-associated PAH.
与系统性红斑狼疮(SLE)或混合性结缔组织病(MCTD)相关的肺动脉高压(PAH),与其他类型的PAH不同,可能对免疫抑制治疗有反应。大多数对免疫抑制剂有反应的PAH病例处于疾病早期(世界卫生组织功能分级为III级或更低)。本病例为一名34岁患有MCTD相关PAH(世界卫生组织功能分级为IV级)的女性,对三种血管扩张剂联合治疗耐药。之后,她接受了糖皮质激素和环磷酰胺治疗。该病例提示免疫抑制剂对重度MCTD相关PAH患者可能有益。